Report: Dendreon looking for buyer

Share this article:

Dendreon's continued slump appears to have forced its hand: Bloomberg reported Monday that the drugmaker, known for its prostate cancer med Provenge, has asked JPMorgan Chase to help it find a buyer.

Dendreon's financial forecasts have been dim: the company managed to narrow its losses during the second quarter, but said in August that it would not be able to hit its 2013 sales target, despite proof that potential patients were responding to its television ads.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.